NASDAQ : BLRX
BioLineRx Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 1.99 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 10.41M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.50M |
| Enterprise Value | 7.33M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 23, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 2.62B |
| Shares Change (YoY) | +49.35% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 0.34% |
| Owned by Institutions (%) | 1.34% |
| Float | 2.83B |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.83 |
| Forward PS | 5.24 |
| PB Ratio | 0.57 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.20 |
| Quick Ratio | 1.01 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.01 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -55.27% |
| Return on Assets (ROA) | -19.82% |
| Return on Invested Capital (ROIC) | -26.58% |
| Return on Capital Employed (ROCE) | -61.46% |
| Weighted Average Cost of Capital (WACC) | 9.01% |
| Revenue Per Employee | $58,000 |
| Profits Per Employee | -$291,208 |
| Employee Count | 24 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.11 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -43.14% |
| 50-Day Moving Average | 2.39 |
| 200-Day Moving Average | 2.74 |
| Relative Strength Index (RSI) | 35.39 |
| Average Volume (20 Days) | 13,824 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 136,917 |
| Short Previous Month | 145,570 |
| Short % of Shares Out | 2.75% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.39M |
| Gross Profit | 1.11M |
| Operating Income | -12.17M |
| Pretax Income | -10.14M |
| Net Income | -6.99M |
| EBITDA | -12.12M |
| EBIT | -12.17M |
| Loss Per Share | -$1.50 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 13.08M |
| Total Debt | 7.94M |
| Net Cash | 5.14M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 16.62M |
| Book Value Per Share | 0.01 |
| Working Capital | 2.67M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.80M |
| Capital Expenditures | -25,000 |
| Depreciation & Amortization | 52,000 |
| Net Borrowing | -4.87M |
| Free Cash Flow | -10.83M |
| FCF Per Share | -$0.00 |
Margins
| Measure | Value |
|---|
| Gross Margin | 80.03% |
| Operating Margin | -874.28% |
| Pretax Margin | -728.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -49.35% |
| Shareholder Yield | -49.35% |
| Earnings Yield | -75.33% |
| FCF Yield | -113.95% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $22.00 |
| Price Target Difference | 1,005.53% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 88.01% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -17.51 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |